On February 27, 2026, Amazon.com, Inc. said it would invest $50 billion in OpenAI as part of the AI firm's $110 billion private funding round, valuing OpenAI at $730 billion pre-money. The multi-year arrangement also designates Amazon Web Services as OpenAI's exclusive third-party cloud provider and expands OpenAI's AWS usage by $100 billion over eight years. Amazon shares traded around $208.21 with a modest intraday gain and a market cap near $2.218 trillion following the announcement.

On February 27, 2026, Moderna's stock fluctuated as the European Medicines Agency's CHMP issued a positive opinion for mCOMBRIAX, its combination influenza and COVID-19 vaccine for adults 50 and older. The shares initially spiked but then traded at $51.06, down 1.27% in early U.S. trading, even as Phase 3 data supported the recommendation and analysts remained divided on the company's outlook.

On February 26, 2026, Nvidia shares dropped about 5% even though the company exceeded Q4 fiscal 2026 estimates and guided above expectations for Q1 revenue. The stock fell to roughly $185 in morning trading as investors focused on concerns about future AI data center growth, competitive pressure and management's preference for reinvestment over shareholder payouts.

Hormel Foods posted first-quarter FY2026 net sales of $3.03 billion with 2% organic growth, while Celsius Holdings reported $2.5 billion in 2025 revenue and fourth-quarter sales of $721.6 million, up 117%. Donaldson Company delivered record second-quarter FY2026 sales of $896 million and outlined segment trends and pricing tailwinds.

The Trade Desk stock dropped more than 16% in premarket trading on February 26, 2026 after its outlook for first-quarter 2026 revenue came in below analyst expectations. The company had just posted fourth-quarter 2025 results that slightly beat on revenue and earnings, but a softer near-term forecast and lack of full-year guidance weighed heavily on investor sentiment.

On February 25, 2026, Intuitive Machines said it entered a definitive agreement to raise $175 million by selling Class A common stock, with closing expected on February 27. Shares fell about 16% to $15.80 in morning trading as dilution weighed on sentiment. Proceeds will fund satellite communications and data-processing networks following the January acquisition of Lanteris Space Systems.

AMD and Meta unveiled a five-year AI chip partnership valued at up to $60 billion to deploy as much as 6 gigawatts of AMD Instinct GPUs. AMD shares were up as much as 15% in premarket trading; as of 8:16 AM EST on February 24, the stock traded at $214.35 after a $196.60 close on February 23.

On February 23, 2026, shares of Arcellx surged after Gilead Sciences agreed to buy the biotech company in a transaction valuing it at about $7.8 billion, including a $115 per share cash offer. The deal adds a potential $5 per share contingent value right tied to sales of Arcellx's CAR-T therapy anito-cel, while the stock price spiked to around $113.95 on heavy trading volume. The acquisition, expected to close in the second quarter of 2026, follows an existing partnership and could become accretive to Gilead's earnings after potential FDA approval.

On February 23, 2026, Vanda Pharmaceuticals shares surged to $8.17 in premarket trading, up 41.84% from the prior close after the FDA cleared its new drug BYSANTI for adult Bipolar I manic episodes and schizophrenia. The approval, Vanda's second since December 2025, extends patent protection to 2044 and supports plans for a commercial launch in Q3 2026, boosting sentiment around the company's growth prospects.